Prelude Therapeutics Inc (PRLD): Insider Trading, Congress Trades & Research | Tormere

PRLD

$3.88+4.86%visit website download financials (.py)

Prelude Therapeutics Inc

Market Cap

$309M

Live price × shares (2026-10-17)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

0.94

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

13.8

Price / TTM revenue

P/B

2.3

Price / stockholders equity

EV/EBITDA

—

TTM

Price Chart

Loading…

Signals

Insider Velocity

no recent activity

purchases / sales, 90d

Market & Alt Data

News

15

recent articles

Analyst Consensus

Strong Buy

9 analysts

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-04-21	2026-04-23	Bonita David P	Director	Purchase	2.82M	$4.44	$12.50M	11.81M	View
2026-04-21	2026-04-23	ORBIMED ADVISORS LLC	Director	Purchase	2.82M	$4.44	$12.50M	11.81M	View

Recent News

Can Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength?

Yahoo · 2026-10-27

Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option

Yahoo · 2026-10-23

Prelude Therapeutics to Participate in the Chardan Healthcare Conference

Yahoo · 2026-10-16

Down 27.4% in 4 Weeks, Here's Why Prelude Therapeutics (PRLD) Looks Ripe for a Turnaround

Yahoo · 2026-10-16

Eli Lilly (LLY) Reported One Year Steroid Free Control In Difficult IBD

Yahoo · 2026-10-15

Prelude Therapeutics Teams Up With Lilly To Test Experimental Breast Cancer Drug In Phase 1 Trial

Yahoo · 2026-10-13

Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer

Yahoo · 2026-10-13

Prelude Therapeutics Enters Clinical Trial Collaboration And Supply Agreement With Eli Lilly For Supply Of Its CDK4/6 Kinase Inhibitor, Abemaciclib And Its Oral Estrogen Receptor Antagonist Imlunestrant

Benzinga · 2026-10-13

Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Yahoo Finance · 2026-09-11

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader

Yahoo Finance · 2026-09-10

Prelude Therapeutics: A Prognosis After Year Long Rally (NASDAQ:PRLD)

Seeking Alpha · 2026-08-23

Prelude Therapeutics (PRLD) Stock Rallies As Losses Ease But Milestones Remain Unclear

Simply Wall Street · 2026-08-11

$PRLD stock is up 19% today. Here's what we see in our data.

Quiver Quantitative · 2026-07-28

Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why

Yahoo Finance · 2026-07-17

Goldman Sachs Initiates Coverage of Prelude Therapeutics (PRLD)

Yahoo Finance · 2026-05-31

Informational purposes only, not investment advice.

Recent Insider Activity (Form 4) — Last 5

Date	Insider	Type	Shares	Value
2026-04-21	Bonita David P	P	1,689,189	$7M
2026-04-21	Bonita David P	P	1,126,126	$5M
2026-04-21	ORBIMED ADVISORS LLC	P	1,689,189	$7M
2026-04-21	ORBIMED ADVISORS LLC	P	1,126,126	$5M